UNSPSC 42203903: Medical neutron radiation therapy systems

In this classification, this commodity indicates a system consisting of products, consumables and accessories that are used to execute a medical neutron radiation therapy procedure in a medical setting. US FDA regulates Medical neutron radiation therapy systems under 21 CFR 892.53 and under FDA product code IWL. Most nations, for tariff and trade purposes, schedule these products under HS 901819.

UNSPSC 42203903 Medical neutron radiation therapy systems, a Commodity code, addresses procurement of specialized equipment for neutron-beam cancer treatment — a narrow and capital-intensive category that state and local governments access primarily through hospital systems, cancer centers, and health authorities rather than direct purchase. The code encompasses the complete therapy apparatus, including the neutron source (accelerator or reactor-based), beam delivery and shaping systems, treatment planning software, patient positioning and immobilization hardware, and associated safety and monitoring instrumentation. Purchase decisions in this category are driven by clinical need, lengthy regulatory approval cycles, and substantial upfront capital investment; buying organizations typically include state university hospital systems, county health departments operating cancer treatment facilities, and municipal or special-purpose health authorities operating comprehensive cancer centers.

The source provided contains no recent state and local contract opportunities tagged to UNSPSC 42203903. Without posted solicitations, RFQs, RFPs, or ITBs naming this code, geographic activity cannot be characterized and representative recent opportunities cannot be identified. The absence of recent procurement records under this code likely reflects the low frequency of neutron therapy system acquisitions — these are multi-million-dollar capital projects with long procurement cycles that do not generate annual or routine buying activity. Organizations seeking intelligence on neutron therapy system procurement should monitor health authority capital-planning timelines, FDA/state radiological safety approvals, and direct outreach to regional cancer centers and academic medical centers rather than relying on this code's recent activity signal.